|
Castanon E, Sanchez-Arraez A, Alvarez-Mancenido F, Jimenez-Fonseca P, Carmona-Bayonas A. Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings. Eur J Cancer. 2020 Sep;136:159-168. doi: 10.1016/j.ejca.2020.06.003. Epub 2020 Jul 19. Erratum In: Eur J Cancer. 2020 Nov 5;: PubMed PMID: 32698098.
AÑO: 2020; IF: 9.162
|
32698098
|
Penas-Martinez J, Luengo-Gil G, Espin S, Bohdan N, Ortega-Sabater C, Rodenas MC, Zaragoza-Huesca D, Lopez-Andreo MJ, Plasencia C, Vicente V, Carmona-Bayonas A, Martinez-Martinez I. Anti-Tumor Functions of Prelatent Antithrombin on Glioblastoma Multiforme Cells. Biomedicines. 2021 May 7;9(5):523. doi: 10.3390/biomedicines9050523. PubMed PMID: 34067120; PubMed Central PMCID: PMC8151964.
AÑO: 2021; IF: 4.757
|
|
Carmona-Bayonas A, Calderon C, Hernandez R, Fernandez Montes A, Castelo B, Ciria-Suarez L, Antonanzas M, Rogado J, Pacheco-Barcia V, Asensio Martinez E, Ivars A, Ayala de la Pena F, Jimenez-Fonseca P. Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy. NPJ Breast Cancer. 2021 Jul 13;7(1):92. doi: 10.1038/s41523-021-00296-8. PubMed PMID: 34257315; PubMed Central PMCID: PMC8277774.
AÑO: 2021; IF: 3.307
|
|
Castanon E, Sanchez-Arraez A, Jimenez-Fonseca P, Alvarez-Mancenido F, Martinez-Martinez I, Mihic Gongora L, Carmona-Bayonas A. Bayesian interpretation of immunotherapy trials with dynamic treatment effects. Eur J Cancer. 2022 Jan;161:79-89. doi: 10.1016/j.ejca.2021.11.002. Epub 2021 Dec 18. PubMed PMID: 34933154.
AÑO: 2022; IF: 8.4
|
|
Vicente Conesa MA, Zafra Poves M, Carmona-Bayonas A, Ballester Navarro I, de la Morena Barrio P, Ivars Rubio A, Montenegro Luis S, Garcia Garre E, Vicente V, Ayala de la Pena F. A prognostic model to identify short survival expectancy of medical oncology patients at the time of hospital discharge. ESMO Open. 2022 Feb;7(1):100384. doi: 10.1016/j.esmoop.2022.100384. Epub 2022 Feb 7. PubMed PMID: 35144121; PubMed Central PMCID: PMC8844687.
AÑO: 2022; IF: 6.883
|